Navigation Links
Baxa Corporation Bolsters Patient Safety With ExactaMix® Compounder Software Upgrade
Date:11/2/2011

ENGLEWOOD, Colo., Nov. 2, 2011 /PRNewswire/ -- Baxa Corporation, a leading provider of medical devices and systems that automate pharmacy operations, has released a software upgrade for its ExactaMix® Automated Compounding Devices (ACD).  The new functionality includes 14 updates that provide Directors of Pharmacy with enhanced patient safety measures and features.

Hospital pharmacies worldwide use ExactaMix 2400 (EM2400) and ExactaMix 1200 (EM1200) to compound large- and small-volume parenteral doses.  Baxa Corporation leads the ACD category with 65% of the global US market share, according to a recent poll in Pharmacy Purchasing & Products magazine.

Improved Efficiency, Added Safety Set Industry Standard

ExactaMix ACDs automatically compound multi-ingredient sterile doses, minimizing the risk of measurement errors, wrong drug selection, touch contamination and patient infection in the preparation of solutions for total parenteral nutrition (TPN), cardioplegia, dialysis and epidural delivery.  

To facilitate the upgrade, current ExactaMix customers will have one-on-one live installation support.  The ExactaMix software release includes the following key features for EM2400 and EM1200 users:

  • Water is now the default calibration ingredient for the US market.  The calibration source was redefined to allow multiple water calibration products.
  • The current patient formula is unloaded when the user exits the compounder screen, reducing the potential for the user to pump a wrong formula into the bag.
  • New priming process improves the purging of air bubbles in the inlets prior to pumping, enhancing the user prime process.
  • Integration with DoseEdge® Pharmacy Workflow Manager enables pharmacies to export MixCheck™ Report data for use with DoseEdge TPN.

State-of-the-art Baxa compounding technology delivers final bag accuracies within + 3% with barcode ingredient verification, and pumps a typical three-liter nutrition bag in approximately 3.5 minutes – nearly two times faster than the industry average.  ExactaMix provides volumetric delivery and gravimetric check with the ability to mix both micro and macro ingredients as low as 0.2 mL.  ExactaMix compounding efficiency enables pharmacy professionals to focus on patient care with the confidence that safety, regulatory compliance and preparation accuracy goals are met.

"The first company to offer automated compounding of both micro and macro ingredients in a single device, Baxa ACDs now serve over 20,000 patients daily across the globe," said Mark Miller, Product Manager at Baxa Corporation.  "In fact, 2012 marks the 10-year anniversary of doses compounded safely on the ExactaMix 2400 Compounder."

Baxa Corporation reliably and consistently enables pharmacists in more than 3,000 hospitals worldwide to safely prepare and administer intravenous therapies.  To learn more about the ExactaMix line of ACDs, visit www.baxa.com/exactamix/.  

For additional information on Baxa IV automation, to request a product brochure or download a free, educational white paper, visit www.baxa.com/ivroom/, call 800.567.2292 or email info@baxa.com.

About Baxa Corporation

Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for medication handling and delivery.  Its systems and devices promote the safe and efficient preparation, handling, packaging and administration of medications.  Key products used worldwide in hospitals and healthcare facilities include: the Abacus® Order Entry and Calculation Software, the DoseEdge® Pharmacy Workflow Manager, ExactaMed® Oral Syringes, ExactaMix® Automated Compounding Devices, InFuse™ and MicroFuse® Syringe Infusers, Repeater™ Pharmacy Pumps, NeoThrive® Enteral Syringes, the PadLock® Set Saver and the RapidFill™ and IntelliFill® i.v. Automated Syringe Fillers.  Privately held, Baxa Corporation has subsidiaries and sales offices in Florida, Canada and the United Kingdom; direct representation in Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, The Netherlands and Switzerland; and distribution partners worldwide.  Further information is available at www.baxa.com.

Contact:
Marian Robinson, Vice President, Marketing
Baxa Corporation:  800.567.2292 ext. 2157 or 303.617.2157
Email:  marian.robinson@baxa.com

Perrin McCormick
HB: 781-893-0053
Email: baxa@hbagency.com


'/>"/>
SOURCE Baxa Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. CEL-SCI Corporation Releases Letter to Shareholders
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
5. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
6. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
7. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
10. Immunosyn Corporation Releases SF-1019 Study Results
11. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... , May 30, 2016 - DCGI grants ... due to Buerger,s disease - Stempeucel® becomes 5th off-the-shelf ... in the world - Buerger,s Disease (also known as ... India and Globally - Prevalence of Buerger,s ... and 2 per 10,000 persons in the European Community & ...
(Date:5/27/2016)... India , May 27, 2016 ... the instances of hypertension is driving ambulatory blood pressure ... lose their elasticity and their ability to respond to ... pressure. This condition can lead to various cardiovascular disorders ... peripheral vascular disease. These diseases are growing in prevalence ...
(Date:5/26/2016)... , May 26, 2016 According to ... Waste Management Market - U.S. Industry Analysis, Size, Share, Growth, ... market in the U.S. was valued at US$ 5.89 Bn ... of 3.4% from 2015 to 2023 to reach US$ 7.99 ... of current and emerging needle free drug delivery devices and ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at ... inspiring human interest stories, courtesy of leaders in the nursing and health care ... industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones & ...
(Date:5/27/2016)... Wis. (PRWEB) , ... May 27, 2016 , ... ... $90,000 in scholarships to students studying complementary medicine. Allison Outerbridge is this year’s ... accepted her award on May 18 at the university’s Student Leadership Awards ceremony. ...
(Date:5/26/2016)... ... , ... Despite last week’s media reports hinting at a June rate hike ... March 2017 for an interest rate increase, according to Rajeev Dhawan of the Economic ... Federal Open Market Committee (FOMC) dot charts are of interest to the press for ...
(Date:5/26/2016)... ... , ... W.S. Badger Co. Inc ., the maker of certified organic ... Works Award for its use of effective workplace strategies to increase business and employee ... by the Families and Work Institute (FWI) and the Society for Human Resource Management ...
(Date:5/26/2016)... ... 26, 2016 , ... Intalere, the healthcare industry leader in ... inaugural Member Conference at the Paris Hotel in Las Vegas, Nev., May 17-20, ... America’s healthcare providers. , The conference was highlighted by the announcement of the ...
Breaking Medicine News(10 mins):